title: Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
abstract: B-cell lymphoproliferative disorders comprise 85% of Non-Hodgkin's lymphomas. Despite successful chemoimmunotherapy regimens, responses are not durable and the outcome is fatal in a considerable portion of patients. There is an inevitable need for less toxic and more potent therapeutic agents. Over the recent years, a plethora of agents including monoclonal antibodies, Bcl-2 antagonists, tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors, mTOR inhibitors and immunomodulatory drugs have been developed in B-cell malignancies. The aim of this paper is to focus on B-cell receptor signaling inhibitors and lenalidomide as an immunomodulatory drug and to provide insight on how and when to incorporate these agents into the treatment algorithms.
authors.affiliation: a Department of Internal Medicine, Division of Haematology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey.
authors.forename: Ayse
authors.initials: A
authors.lastname: Salihoglu
authors.affiliation: a Department of Internal Medicine, Division of Haematology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey.
authors.forename: Muhlis Cem
authors.initials: MC
authors.lastname: Ar
authors.forename: Teoman
authors.initials: T
authors.lastname: Soysal
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000473:pathology*; D006801:Humans; D000077269:Lenalidomide; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D015398:Signal Transduction; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: B-cell malignancy; B-cell receptor signaling pathway inhibitor; duvelisib; fostamatinib; ibrutinib; idelalisib; immunomodulatory drugs; lenalidomide; non-Hodgkin’s lymphoma